We will review hereafter the contribution of systemic elements not located in the TME but which can substantially affect tumor development and immunotherapy success, including soluble factors and circulating cell populations with a special focus on the role of PD-L1 as a major immune regulator (Table 1). This evidence concerns the gene CD274 and neoplasm.